Tag Breast Cancer

Truqap in combination with Faslodex approved in the EU for the treatment of ER-positive, HER2‑negative locally advanced or metastatic breast cancer

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or…

Positive long-term follow-up data from the pivotal, Phase 3 KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment.

Roche announced positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. “We are pleased that Kadcyla could offer people with…

Positive results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

Genentech, a member of the Roche Group, announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor…

Positive topline results from the TROPION-Breast01 Phase 3 trial.

Positive topline results from the TROPION-Breast01 Phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progressionfree survival (PFS) compared to investigator’s choice of chemotherapy in patients with inoperable or…